Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME 11:35:54 2024-06-21 am EDT 5-day change 1st Jan Change
9.12 EUR +0.82% Intraday chart for Grifols, S.A. -0.74% -40.99%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Traded in the US as American Depositary Receipts Move Higher in Thursday Trading MT
Haier Gets Regulatory Nod to Buy Controlling Stake in RAAS Blood Products MT
RAAS Blood Products Renews Cooperation Deal With Spain's Grifols MT
European Equities Close Higher in Tuesday Trading; Euro Area, EU Inflation Rises in May MT
Grifols Sells 20% Stake in Shanghai RAAS to Haier Group for $1.72 Billion MT
Grifols Completes Shanghai RAAS 20% Stake Sale to Haier MT
Haiyingkang Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. from Grifols, S.A.. CI
Sector Update: Health Care Stocks Retreat Late Afternoon MT
Grifols' Biotest Gets FDA Approval for Yimmugo MT
Grifols' Biotest Wins US FDA Approval for Primary Immunodeficiency Treatment MT
Grifols, S.A. Announces Board and Committee Changes CI
Solaria shares jump on report of takeover interest RE
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading MT
Grifols, S.A. Reports the Successful Closing of the Private Placement of Additional 7.5% Senior Secured Notes Due 2030 CI
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading MT
Solaria expects energy prices to rise this year RE
Solaria sees higher energy prices later this year, shares rise RE
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading MT
GRIFOLS : In line Q1 and on track deleveraging; worth a go Alphavalue
Chart Grifols, S.A.
More charts
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
9.12 EUR
Average target price
17.53 EUR
Spread / Average Target
+92.23%
Consensus
  1. Stock Market
  2. Equities
  3. GRF Stock
  4. News Grifols, S.A.
  5. Grifols Shares Rise as Haier Deal Set to Close in June